That would boost payments for CAR T-cell therapy from $186,500 to $242,450.
Their T cells, which are immune cells, are extracted, sent to a special lab and genetically modified to attack a protein on the surface of the cancer cells.
Roy Silverstein, president of the American Society of Hematology, said on Tuesday he was pleased CMS responded to the groupâ€™s concerns about inadequate inpatient reimbursement for CAR T-cell therapy.
ADADEarlier this year, CMS separately proposed a national policy to cover the therapy for Medicare patients, but with certain restrictions.
Currently, coverage decisions for CAR T-cell therapy are left up to local Medicare administrators.